Sadis & Goldberg Retained to Investigate Allegations of Accounting Fraud at Meihua International Medical Technologies Co., Ltd. (MHUA)

Rhea-AI Summary

Sadis & Goldberg has been engaged by stockholders of Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA) to investigate alleged accounting fraud involving the company’s financial statements. The investigation follows MHUA's failure to timely file its Annual Report, leading to the resignation of both its independent auditor and the chairman of its Audit Committee. These developments have caused MHUA's stock price to plummet from $14.80 to $5.30, raising serious concerns about the accuracy of its financial disclosures and potential violations of NASDAQ Rules.

Positive

• None.

Negative

• Allegations of accounting fraud may lead to further investigations and legal actions, impacting company reputation.
• Stock price decline from $14.80 to $5.30 raises concerns among investors.
• Resignation of independent auditor and Audit Committee chairman indicates potential governance issues.
• Failure to file Annual Report timely is a violation of NASDAQ Rules.

News Market Reaction – MHUA

-1.89%

1 alert

-1.89% News Effect

On the day this news was published, MHUA declined 1.89%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, July 20, 2022 /PRNewswire/ -- Sadis & Goldberg has been retained by stockholders of Meihua International Medical Technologies Co., Ltd. (NASDAQ:  Ticker "MHUA") to investigate alleged accounting fraud by MHUA and/or its officers and directors. Our investigation focuses on MHUA's violation of NASDAQ Rules by failing to timely file its Annual Report containing its financial statements.  Shortly thereafter, MHUA's independent Auditor resigned, as did the Chairman of MHUA's Audit Committee. As a result, MHUA's stock price has fallen from as high as $14.80 per share to $5.30.

Our investigation focuses on a violation of NASDAQ Rules by failing to timely file its Annual Report.

These developments raise major concern that MHUA's current and prior financial statements are false and misleading. Further, they raise serious concerns that MHUA, its officers and/or directors may have presented false and misleading financial information in the Prospectus for MHUA's Initial Public (IPO) in February 2022.  Sadis & Goldberg is investigating potential direct and derivative claims that MHUA and its officers and directors breached their fiduciary duties, engaged in common law fraud, and/or violated securities laws through false accounting and financial statements. 

If you are an investor in MHUA, and wish to obtain additional information to protect your investment or recover losses, please contact Samuel J. Lieberman of Sadis & Goldberg at (212) 573-8164 or by email at SLieberman@sglawyers.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sadis--goldberg-retained-to-investigate-allegations-of-accounting-fraud-at-meihua-international-medical-technologies-co-ltd-mhua-301590078.html

SOURCE Sadis & Goldberg LLP

FAQ

What is the investigation about Meihua International Medical Technologies Co., Ltd. (MHUA)?

The investigation focuses on alleged accounting fraud and MHUA's failure to file its Annual Report on time.

How much did MHUA's stock price drop?

MHUA's stock price dropped from $14.80 to $5.30.

Who is leading the investigation into MHUA?

The investigation is being led by Sadis & Goldberg on behalf of MHUA's stockholders.

What are the concerns regarding MHUA's financial statements?

There are serious concerns that MHUA's current and prior financial statements may be false and misleading.

What actions have been taken by MHUA in response to the investigation?

MHUA's independent auditor and the chairman of its Audit Committee have resigned.